Article thumbnail
Location of Repository

Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

By Thomas Kuehr, Paul Ruff, Bernardo L Rapoport, Stephen Falk, Francis Daniel, Conrad Jacobs, Neville Davidson, Josef Thaler, Blandine Boussard and James Carmichael

Abstract

BACKGROUND: This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer. METHODS: Sixty-three patients received irinotecan (250 or 300 mg/m(2), 30- to 90-minute intravenous infusion on day 1), immediately followed by folinic acid (20 mg/m(2)/day) and 5-fluorouracil (425 mg/m(2), 15-minute bolus infusion) days 1 to 5, every four weeks. RESULTS: Diarrhoea was dose limiting at 300 mg/m(2 )irinotecan in combination with 5-fluorouracil and folinic acid, and this was determined to be the maximum tolerated dose. Grade 3–4 neutropenia was the most frequently reported toxicity. The recommended dose of irinotecan for the phase II part of the study was 250 mg/m(2). The response rate for the evaluable patient population was 36% (13/36), and 44% (16 patients) had stable disease (including 19% of minor response). For the intention-to-treat population, the response rate was 29% (14/49) and 35% (17 patients) stable disease (including 14% of minor response). The median time to progression was 7.0 months and the median survival was 12.0 months. Grade 3–4 non-haematological drug-related toxicities included delayed diarrhoea, stomatitis, fatigue, and nausea/vomiting. There were three deaths due to septic shock that were possibly or probably treatment-related. CONCLUSIONS: This regimen of irinotecan in combination with the Mayo Clinic schedule of bolus 5-fluorouracil/folinic acid every four weeks showed activity as first-line therapy in patients with advanced colorectal cancer. In keeping with other published results of studies using bolus 5-fluorouracil combined with irinotecan, the use of this regimen is limited by a relatively high rate of grade 3–4 neutropenia, and the combination of irinotecan and infusional 5-fluorouracil / folinic acid should remain the regimen of first choice

Topics: Research Article
Publisher: BioMed Central
Year: 2004
DOI identifier: 10.1186/1471-2407-4-36
OAI identifier: oai:pubmedcentral.nih.gov:493270
Provided by: PubMed Central

Suggested articles

Citations

  1. (1999). Bleiberg H: Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
  2. (1998). C: A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first line chemotherapy of metastatic colorectal cancer. Ann Oncol
  3. (1998). C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after failure in patients with metastatic colorectal cancer. Lancet
  4. (1994). Donehower RC: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res
  5. (1994). Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
  6. (1997). HE: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
  7. (1998). Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet
  8. (1996). Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
  9. (1999). Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and highdose leucovorin every two weeks (LV5FU2 regimen): a dose finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
  10. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet
  11. (1996). Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
  12. (2003). Irinotecan Study Group: A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Ann Oncol
  13. (1996). Kelsen DP: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
  14. (2000). LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
  15. (1995). Mangalik A: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study.
  16. (2001). MJ: Oxaliplatin or CPT-11 combined with 5-FU/Leucovorin in advanced colorectal cancer: an NCCTG/CALGB study [abstract]. Proc Am Soc Clin Oncol
  17. (2001). Mortality associated with irinotecan plus bolus fluorouracil/ leucovorin: summary findings of an independent panel.
  18. (1998). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials
  19. (1995). Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
  20. (1999). Phase I study of a weekly schedule of irinotecan, high dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
  21. (1997). Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and pretreated patients with fluorouracil-based chemotherapy.
  22. (2002). Pyrhonen S: Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol
  23. (1997). RJ: A phase II multicenter trial of alternating cycles of irinotecan and 5FU/LV in patients with previously untreated metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol
  24. (2001). RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
  25. (2001). Rustum YM: Irinotecan in the treatment of colorectal cancer: clinical overview.
  26. (1992). The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate.
  27. (1994). Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev
  28. (1989). Tschetter LK: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.